JP7374765B2 - 抗dkk-1抗体を使用して癌を治療するためのバイオマーカーとしてのベータ-カテニンの使用 - Google Patents

抗dkk-1抗体を使用して癌を治療するためのバイオマーカーとしてのベータ-カテニンの使用 Download PDF

Info

Publication number
JP7374765B2
JP7374765B2 JP2019522823A JP2019522823A JP7374765B2 JP 7374765 B2 JP7374765 B2 JP 7374765B2 JP 2019522823 A JP2019522823 A JP 2019522823A JP 2019522823 A JP2019522823 A JP 2019522823A JP 7374765 B2 JP7374765 B2 JP 7374765B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
dkk
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019522823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533693A (ja
Inventor
ケーギー,マイケル,エイチ.
シラード,シンシア,エイ.
Original Assignee
リープ セラピューティクス,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リープ セラピューティクス,インコーポレイテッド filed Critical リープ セラピューティクス,インコーポレイテッド
Publication of JP2019533693A publication Critical patent/JP2019533693A/ja
Priority to JP2023121862A priority Critical patent/JP2023133432A/ja
Application granted granted Critical
Publication of JP7374765B2 publication Critical patent/JP7374765B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019522823A 2016-10-26 2017-10-26 抗dkk-1抗体を使用して癌を治療するためのバイオマーカーとしてのベータ-カテニンの使用 Active JP7374765B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023121862A JP2023133432A (ja) 2016-10-26 2023-07-26 抗dkk-1抗体を使用して癌を治療するためのバイオマーカーとしてのベータ-カテニンの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662413198P 2016-10-26 2016-10-26
US62/413,198 2016-10-26
PCT/US2017/058555 WO2018081437A1 (en) 2016-10-26 2017-10-26 Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023121862A Division JP2023133432A (ja) 2016-10-26 2023-07-26 抗dkk-1抗体を使用して癌を治療するためのバイオマーカーとしてのベータ-カテニンの使用

Publications (2)

Publication Number Publication Date
JP2019533693A JP2019533693A (ja) 2019-11-21
JP7374765B2 true JP7374765B2 (ja) 2023-11-07

Family

ID=60570180

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019522823A Active JP7374765B2 (ja) 2016-10-26 2017-10-26 抗dkk-1抗体を使用して癌を治療するためのバイオマーカーとしてのベータ-カテニンの使用
JP2023121862A Pending JP2023133432A (ja) 2016-10-26 2023-07-26 抗dkk-1抗体を使用して癌を治療するためのバイオマーカーとしてのベータ-カテニンの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023121862A Pending JP2023133432A (ja) 2016-10-26 2023-07-26 抗dkk-1抗体を使用して癌を治療するためのバイオマーカーとしてのベータ-カテニンの使用

Country Status (14)

Country Link
US (2) US11267876B2 (cg-RX-API-DMAC7.html)
EP (1) EP3532099A1 (cg-RX-API-DMAC7.html)
JP (2) JP7374765B2 (cg-RX-API-DMAC7.html)
KR (1) KR102701695B1 (cg-RX-API-DMAC7.html)
CN (1) CN110114087A (cg-RX-API-DMAC7.html)
AU (1) AU2017347822B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019008279A2 (cg-RX-API-DMAC7.html)
CA (1) CA3041325A1 (cg-RX-API-DMAC7.html)
IL (1) IL266199B2 (cg-RX-API-DMAC7.html)
MA (1) MA46673A (cg-RX-API-DMAC7.html)
MX (1) MX2019004940A (cg-RX-API-DMAC7.html)
RU (1) RU2019115946A (cg-RX-API-DMAC7.html)
SG (1) SG11201903602RA (cg-RX-API-DMAC7.html)
WO (1) WO2018081437A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3041325A1 (en) 2016-10-26 2018-05-03 Leap Therapeutics, Inc. Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
AU2020216494A1 (en) * 2019-02-01 2021-08-12 Board Of Regents, The University Of Texas System Monoclonal antibodies against MHC-bound human Dickkopf-1 peptides and uses thereof
US20220381786A1 (en) * 2019-09-19 2022-12-01 Leap Therapeutics, Inc. Use of dkk-1 inhibitors for treating cancer
KR20220131223A (ko) * 2019-11-22 2022-09-27 리프 테라퓨틱스 인코포레이티드 Dkk-1 억제제를 사용하여 암을 치료하는 방법
WO2023143444A1 (zh) 2022-01-28 2023-08-03 上海君实生物医药科技股份有限公司 抗dkk1抗体、其药物组合物及用途
EP4499126A4 (en) * 2022-03-24 2026-03-25 Translational Genomics Res Inst PEPTIDE INHIBITORS TARGETTING THE TBL1-BETA-CATENIN COMPLEX
CN118924886A (zh) * 2023-03-16 2024-11-12 郑州大学 肿瘤共享新抗原表位肽或其编码核酸的新用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
CN101641373B (zh) * 2007-02-08 2015-02-11 默沙东公司 Dkk-1的特异性抗体
EP2190478B1 (en) 2007-08-24 2016-03-23 Oncotherapy Science, Inc. Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
AR075989A1 (es) 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
KR20120117621A (ko) 2009-05-07 2012-10-24 노파르티스 아게 딕코프-1 또는 딕코프-4 또는 둘 모두에 대한 결합 분자에 대한 조성물 및 사용 방법
AU2011223655A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CN103608037B (zh) * 2011-02-01 2016-04-13 香港大学 抗dkk1单克隆抗体用于治疗肝癌的用途
JP6465790B2 (ja) * 2013-02-27 2019-02-06 第一三共株式会社 Mapkシグナル伝達経路を阻害する化合物に対する応答性を予測する方法
EP3077546A4 (en) 2013-12-02 2017-04-26 Oncomed Pharmaceuticals, Inc. Identification of predictive biomarkers associated with wnt pathway inhibitors
CA3041325A1 (en) 2016-10-26 2018-05-03 Leap Therapeutics, Inc. Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
US20220381786A1 (en) 2019-09-19 2022-12-01 Leap Therapeutics, Inc. Use of dkk-1 inhibitors for treating cancer
KR20220131223A (ko) 2019-11-22 2022-09-27 리프 테라퓨틱스 인코포레이티드 Dkk-1 억제제를 사용하여 암을 치료하는 방법
WO2023039249A1 (en) 2021-09-10 2023-03-16 Leap Therapeutics, Inc. Combination therapy
US20260077043A1 (en) 2022-07-12 2026-03-19 Leap Therapeutics, Inc. Combination therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Hepatology Res, 2016.10, Vol.46 No.11, p.1145-1151
Journal of ClinicalOncology, Volume 34, Issue 4, Abstract No.111,https://ascopubs.org/doi/abs/10.1200/jco.2016.34.4_suppl.111
日本外科学会雑誌、2002, Vol.103 臨時増刊号 p.350 (PP0172)
日本消化器病学会雑誌、2001, Vol.98 臨時増刊号大会 p.A456 (消P-34)

Also Published As

Publication number Publication date
MX2019004940A (es) 2019-09-26
SG11201903602RA (en) 2019-05-30
AU2017347822B2 (en) 2025-01-16
AU2017347822A1 (en) 2019-05-09
EP3532099A1 (en) 2019-09-04
CA3041325A1 (en) 2018-05-03
KR102701695B1 (ko) 2024-08-30
RU2019115946A (ru) 2020-11-27
IL266199B2 (en) 2025-02-01
IL266199B1 (en) 2024-10-01
US20220289831A1 (en) 2022-09-15
JP2019533693A (ja) 2019-11-21
IL266199A (en) 2019-06-30
CN110114087A (zh) 2019-08-09
RU2019115946A3 (cg-RX-API-DMAC7.html) 2021-01-26
MA46673A (fr) 2019-09-04
WO2018081437A1 (en) 2018-05-03
US20190284264A1 (en) 2019-09-19
BR112019008279A2 (pt) 2019-07-09
US12319730B2 (en) 2025-06-03
JP2023133432A (ja) 2023-09-22
US11267876B2 (en) 2022-03-08
KR20190085935A (ko) 2019-07-19

Similar Documents

Publication Publication Date Title
JP2023133432A (ja) 抗dkk-1抗体を使用して癌を治療するためのバイオマーカーとしてのベータ-カテニンの使用
RU2746812C1 (ru) Способы и композиции для лечения амилоидозов
KR102470294B1 (ko) 암을 치료하기 위한 항-pd1 항체 및 방사선의 조합
US11884734B2 (en) Anti-MET antibodies and methods of use thereof
US20160304595A1 (en) Methods of increasing strength and functionality with gdf8 inhibitors
CN110382532B (zh) 抗g-csf抗体及其用途
US20230131598A1 (en) Combination treatment for cancer
CN114929275A (zh) 使用dkk-1抑制剂治疗癌症的方法
WO2025114357A1 (en) Method of treating disease using anti-cd47 x anti-mesothelin antibodies as a sole agent and in combination with anti-pd-1 antibodies
JP2024529451A (ja) がんを治療するための方法及び組成物
US20230149543A1 (en) Combination treatment for cancer based upon an icos antbody and a pd-l1 antibody tgf-bets-receptor fusion protein
KR20170023414A (ko) 간세포 암종을 위한 항-vegfr2 항체 요법
JP2024533439A (ja) 併用療法
TW202527984A (zh) 5t4抗體藥物結合物及其使用之方法
HK40109234A (en) Methods and compositions for treating cancer
WO2026082966A1 (en) Methods of treating disease using anti-cd47 x anti-mesothelin antibodies in combination with chemotherapy
HK40035170A (en) Methods and compositions for treatment of amyloid deposition diseases

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230727

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230922

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231016

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231025

R150 Certificate of patent or registration of utility model

Ref document number: 7374765

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150